INTERSTITIAL CYSTITIS DRUGS MARKET ANALYSIS

The global interstitial cystitis drugs market is estimated to be valued at US$ 234.9 million in 2023 and is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

Analysts’ Views on Global Interstitial Cystitis Drugs Market:

Increasing adoption of various growth strategies, such as collaboration and others, by market payers is expected to propel market growth over the forecast period. For instance, on September 21, 2023, Lipella Pharmaceuticals, Inc., a biotechnology company, in collaboration with researchers from the University of Pittsburgh, U.S., initiated a research study that distinguishes different types of interstitial cystitis/bladder pain syndrome, which is currently in early phase 1 and actively recruiting patients as volunteers.

Figure 1. Global Interstitial Cystitis Drugs Market Share (%), By Drug Class, 2023

To learn more about this report, request sample copy

Global Interstitial Cystitis Drugs Market– Drivers

Increasing Prevalence of Interstitial Cystitis:

• Rising prevalence of interstitial cystitis is expected to drive market growth over the forecast period. For instance, in August 2022, according to a report published in the National Center for Biotechnology Information, the estimated annual incidence rate of interstitial cystitis in the U.S. was 2.6 cases per 100,000 women every year, while the report also reported that Europe indicated a prevalence of 18 cases per 100,000 women, whereas only 3-4 cases per 100,000 women are reported in Japan every year, respectively.

Rising Healthcare Expenditure

• One of the significant factors influencing the growth rate of the interstitial cystitis drugs market is the growing healthcare expenditure, which helps in improving its infrastructure. For instance, according to the International Health Care System of the U.S., in June 2020, U.S. government organizations aim to improve the healthcare infrastructure by increasing funding, setting legislation and national strategies, and cofounding and setting basic requirements and regulations for the Medicaid program.
• Furthermore, in December 2022, according to a report published by the Centers for Medicare & Medicaid Services, U.S. health care spending grew 2.7% in 2021, reaching US$ 4.3 trillion, or US$ 12,914 per person, while as a share of the nation's gross domestic product, health spending accounted for 18.3%.
• Similarly, in November 2022, the Canadian Institute for Health Information reported that the total health spending in Canada was US$331 billion in 2022, or US$ 8,563 per Canadian, while health expenditure represented 12.2% of Canada's gross domestic product (GDP) in 2022, following a high of 13.8% in 2020.

Figure 2. Global Interstitial Cystitis Drugs Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Interstitial Cystitis Drugs Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global interstitial cystitis drugs market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global interstitial cystitis drugs market is expected to witness significant growth in the coming years, owing to the rising number of clinical trials by market players for the treatment of patients suffering from interstitial cystitis. For instance, on October 3, 2023, Ironwood Pharmaceuticals, Inc., a biotechnology company, announced the initiation of clinical trial to study the safety and efficacy of IW-3300 for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS), which is currently in phase 2 of the clinical trial and actively recruiting patients.

Global Interstitial Cystitis Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems with the transportation of things from one place to another.
• The supply chain and manufacturing activities in India, China, the U.S., and other countries have been disrupted due to lockdown, while countries such as Thailand, Indonesia, and Singapore have faced problems with regards to the transportation of drugs and medical devices.
• Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global interstitial cystitis drugs market during the forecast period, owing to the decrease in production and supply of the drugs during the pandemic.

Global Interstitial Cystitis Drugs Market Segmentation:

The global interstitial cystitis drugs market report is segmented into by drug class, by type and distribution channel.

• By drug class, the market is segmented into non-steroidal anti-inflammatory drugs, tricyclic antidepressants, pentosan polysulfate sodium (Elmiron), dimethyl dulfoxide (DMSO) and others (anti-histamines, etc.). Out of which, the pentosan polysulfate sodium (Elmiron) segment is expected to hold a dominant position in the global interstitial cystitis drugs market during the forecast period, and this is attributed to the rising  prevalence of interstitial cystitis.
• By type, the market is segmented into non-ulcerative and ulcerative. Out of which, the Ulcerative segment is expected to hold a dominant position in the global interstitial cystitis drugs market during the forecast period, and this is attributed to rising  number of clinical trial initiation by market players for the treatment of patients suffering from interstitial cystitis.
• By route of administration, the market is segmented into oral and intravesical. Out of which, oral segment is expected to dominate the market over the forecast period, and this is attributed to increasing product launches by key market players.
• By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies is expected to dominate the market over the forecast period, and this is attributed to the rising number of hospitals globally, which will subsequently demand the need for hospital pharmacies.
• Among all the segmentation, the drug class segment is expected to dominate the market over the forecast period, and this is attributed to the increasing research and development activities.

Global Interstitial Cystitis Drugs Market- Cross Sectional Analysis:

The Oral sub segment is dominating in North America as researchers are focused on research and development activities on oral interstitial cystitis drugs in the North America region, which, in turn, is expected to propel market growth over the forecast period. For instance, in December 2022, researchers from the University of Pittsburgh, U.S., conducted a clinical trial to compare two different treatment patterns in patients with chronic bladder pain and interstitial cystitis, which is currently in Phase 3, and actively recruited patients.

Global Interstitial Cystitis Drugs Market: Key Developments

• On September 15, 2023, West China Hospital, hospital in Chengdu, China, initiated a clinical trial to access the effectiveness and safety of interferon bladder infusions for the treatment of interstitial cystitis.
• On May 22, 2023, Vaneltix Pharma, Inc., a pharmaceutical company, in collaboration with Prevail Infoworks, Inc., a system integration and analytics software company, initiated a clinical trial to study the safety and efficacy of VNX001 compared to its individual components (lidocaine and heparin) or placebo in subjects with IC/BPS, which is currently in Phase 2 of the clinical trial and actively recruiting patients.
• In July 2022, researchers from Stanford University, U.S., initiated a clinical trial to study low-dose naltrexone for bladder pain syndrome, which is currently in Phase 2 of the clinical trial.
• In August 2021, PureTech, a clinical-stage biotherapeutics company, announced that Imbrium Therapeutics, a clinical-stage biopharmaceutical company, had exercised its license option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome. Imbrium Therapeutics had paid PureTech US$ 6.5 million, and PureTech is eligible to receive up to US$ 53 million in additional development milestone payments for this program in addition to royalties on product sales.

Global Interstitial Cystitis Drugs Market: Key Trend

• Rising Number of Awareness Campaign: Increasing initiatives such as awareness campaigns and others for patients suffering from conjunctivitis are expected to boost market growth over the forecast period. For instance, on September 1, 2023, Interstitial Cystitis Network, a health education company, announced the launch of the annual IC (Interstitial Cystitis) Awareness Month campaign, with an aim to help IC/BPS (Interstitial Cystitis(IC)/Bladder Pain Syndrome) patients differentiate between cause and effect.

Global Interstitial Cystitis Drugs Market: Restraint

• Side Effects Associated with the Drugs used in the Treatment of Interstitial Cystitis: Various drugs are used in the treatment of interstitial cystitis, such as pentosan polysulfate sodium (Elmiron) and others. Thus, side effects associated with the drugs used in the treatment of interstitial cystitis are further expected to hamper market growth in the future. For instance, in October 2021, according to a report published by the Commonwealth of Australia, added a warning about pigmentary maculopathy, or changes in the retina of the eye, to the Product Information (PI) and Consumer Medicine Information (CMI) – an external site for pentosan polysulfate sodium. This is considered a rare side effect of pentosan polysulfate sodium, which can lead to visual changes associated with the use of pentosan polysulfate sodium, especially after long-term therapy. Furthermore, some of the common side effects associated with pentosan polysulfate sodium include:
  • Hair loss
  • Diarrhea
  • Upset stomach
  • Heartburn
  • Headache
  • Rash
  • Stomach pain
  • Difficulty falling asleep or staying asleep
  • Moodiness
  • Dizziness
• Counterbalance: To avoid these kinds of side effects, patients must consult their physicians before taking any medications by their own.

Global Interstitial Cystitis Drugs Market - Key Players

Major players operating in the global interstitial cystitis drugs market include AbbVie Inc., Hyloris Pharmaceuticals SA, TAGCyx Biotechnologies, KYORIN Pharmaceutical Co., Ltd., PureTech Health, Vaneltix, Red Leaf Medical Inc., Bayer AG, Eli Lilly and Co, Johnson & Johnson (Janssen Pharmaceuticals), Mylan NV (Viatris Inc.), Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and ImprimisRx (Harrow Health, Inc.)

*Definition: Interstitial cystitis (IC) is a prolonged condition that causes bladder pressure, pain, and, in some cases, pelvic pain. The symptoms of interstitial cystitis may have an impact on one’s social life, physical activity, sleep, and even the ability to work. The disease tends to affect women more than the men. Common symptoms of interstitial cystitis include bladder pain and pressure, frequent urination, pain in the vagina or vulva in women, and pain in the scrotum or testicles in men. It is difficult to diagnose; therefore, even though treatments can improve one's quality of life, there is no optimal cure.